Friday, 16 October 2026European Markets

ARRIBATEC GROUP Stock Went Up By Over 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of ARRIBATEC GROUP (Oslo Børs Benchmark Index_GI: ARR.OL) jumped by a staggering 21.6% in 10 sessions from kr2.92 to kr3.55 at 17:21 EST on Monday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is jumping 0.22% to kr1,227.25, after four consecutive sessions in a row of gains.

About ARRIBATEC GROUP

Arribatec Solutions ASA, a software and consulting company, provides digital business solutions in Norway and internationally. The company offers solutions for businesses, including ERP, Cloud and IT solutions, business intelligence, EA and BPM, software development, hospitality, and marine. Its solutions include QualiWare, an enterprise architecture and business management tool for digital transformation; Unit4, a cloud-based self-driving adaptive and intuitive enterprise software; InfoSHIP, a web-based software suitable for cruise, tanker, cargo, bulk, ferry vessels, and other ships; Boson Go, an app extension to QualiWare; OLKWEB for follow-up, training, and administration of apprentices; Instipro3 for research project management; RamBase, an ERP business platform that gives control over the value chain; Power BI, a tool to get insight into business by combining data from various systems and visualize it in interactive reports and intuitive dashboards; Hypergene, a performance management solution; holographic kiosks; self-service kiosks; Certify Housekeeping tool for daily management of the housekeeping department; GDPR Portal; and Microsoft Azure, a cloud environment solution. The company was founded in 2015 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ARRIBATEC GROUP has a trailing twelve months EPS of kr-1.32.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ARRIBATEC GROUP's stock is considered to be oversold (<=20).

More news about ARRIBATEC GROUP (ARR.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com